Molecular Templates (NASDAQ:MTEM) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Wednesday.

According to Zacks, “Molecular Templates Inc. is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies for the treatment of cancers and other serious diseases. Molecular Templates Inc., formerly known as Threshold Pharmaceuticals Inc., is headquartered in Austin, United States. “

Separately, ValuEngine cut shares of Molecular Templates from a “hold” rating to a “sell” rating in a report on Friday, July 6th.

NASDAQ:MTEM opened at $5.26 on Wednesday. The company has a quick ratio of 3.33, a current ratio of 3.33 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $138.03 million, a price-to-earnings ratio of -2.49 and a beta of 3.05. Molecular Templates has a 12 month low of $4.61 and a 12 month high of $13.25.

Molecular Templates (NASDAQ:MTEM) last posted its quarterly earnings results on Thursday, August 9th. The biotechnology company reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.61. The business had revenue of $1.37 million during the quarter. Molecular Templates had a negative net margin of 509.53% and a negative return on equity of 22.67%. research analysts anticipate that Molecular Templates will post -1.57 EPS for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in shares of Molecular Templates by 41.4% during the first quarter. JPMorgan Chase & Co. now owns 50,020 shares of the biotechnology company’s stock valued at $400,000 after buying an additional 14,635 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Molecular Templates during the fourth quarter valued at about $722,000. Northern Trust Corp grew its holdings in shares of Molecular Templates by 36.7% during the first quarter. Northern Trust Corp now owns 22,152 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 5,948 shares during the last quarter. Wells Fargo & Company MN grew its holdings in shares of Molecular Templates by 1,744.7% during the fourth quarter. Wells Fargo & Company MN now owns 10,035 shares of the biotechnology company’s stock valued at $101,000 after buying an additional 9,491 shares during the last quarter. Finally, Caxton Corp grew its holdings in shares of Molecular Templates by 2.5% during the first quarter. Caxton Corp now owns 1,038,787 shares of the biotechnology company’s stock valued at $8,310,000 after buying an additional 25,000 shares during the last quarter. Hedge funds and other institutional investors own 21.17% of the company’s stock.

Molecular Templates Company Profile

Molecular Templates, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase I clinical trial for the treatment of relapsed/refractory non-Hodgkin's lymphoma and B-cell lymphoma.

Further Reading: How to Use a Moving Average for TradingĀ 

Get a free copy of the Zacks research report on Molecular Templates (MTEM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with MarketBeat.com's FREE daily email newsletter.